JenaValve's Trilogy System Becomes First FDA-Approved TAVR Device for Severe Aortic Regurgitation
核心洞察
JenaValve's Trilogy transcatheter heart valve system (搜索) received FDA premarket approval as the first and only transcatheter device approved for treating symptomatic, severe aortic regurgitation (搜索) in high-risk patients.
The approval was supported by the ALIGN-AR pivotal trial involving 180 high-risk patients, demonstrating effective orifice area, low transvalvular gradients, and low paravalvular regurgitation.
The Trilogy system features proprietary radiopaque locators that attach directly to native aortic leaflets (搜索), enabling secure implantation even without calcium deposits typically required by conventional TAVR valves.
JenaValve Technology (搜索) announced that the U.S. Food and Drug Administration (搜索) has granted premarket approval (PMA) for its Trilogy transcatheter heart valve system (搜索), marking a historic milestone as the first and only transcatheter device approved for treating symptomatic, severe aortic regurgitation (搜索) (AR) in the United States. The approval specifically covers patients at high or greater risk for surgical aortic valve (搜索) replacement.
The designation addresses a significant unmet medical need, as symptomatic, severe AR affects tens of thousands of people annually in the United States and remains significantly undertreated. Aortic regurgitation (搜索) occurs when there is reverse blood flow through the aortic valve (搜索) due to inadequate closure during diastole, resulting in symptoms including shortness of breath, chest pain, and fatigue.
Clinical Evidence Supporting Approval
The FDA approval was supported by successful results from the ALIGN-AR pivotal trial, a prospective, multicenter, single-arm Investigational Device Exemption study. The trial assessed the safety and efficacy of the Trilogy system in 180 high-surgical-risk patients with symptomatic, severe aortic regurgitation (搜索).
In the study population, the Trilogy system demonstrated effective orifice area, low transvalvular gradients, and low paravalvular regurgitation. Martin B. Leon, professor of medicine and director of the Center for Interventional Vascular Therapy at Columbia University Irving Medical Center and global program chair of the ALIGN-AR trial, stated: "With what we have learned about the Trilogy valve from the ALIGN-AR trial, we now have the answer to a question that the cardiology community had struggled with – can we safely and effectively treat patients with severe aortic regurgitation (搜索) with a transcatheter device? The answer is yes."
Innovative Design Features
The Trilogy system was purpose-built to address the unique anatomical challenges of aortic regurgitation (搜索). Unlike conventional TAVR valves that rely on annular calcification for anchoring – which is typically absent in AR patients – the Trilogy system features three proprietary radiopaque locators that attach directly to the native aortic leaflets (搜索).
This design enables secure and stable implantation even in the absence of calcium deposits. The locators also provide commissural alignment for precise valve positioning and ensure a reliable seal to minimize paravalvular regurgitation. The system's large, open-cell nitinol frame is designed to preserve future coronary access.
Leon emphasized the significance of this design innovation: "The unique design of the Trilogy System — with its locator technology providing secure anchoring even in the absence of calcium — addresses the fundamental challenge that has made AR so difficult to treat. This approval establishes a new standard of care for high-risk AR patients and is a landmark achievement for the field of interventional cardiology."
Market Launch and Commercial Impact
JenaValve CEO John Kilcoyne described the approval as "the defining moment for JenaValve and, more importantly, those patients in the United States who have suffered from severe aortic regurgitation (搜索) with nowhere to turn." He added: "For too long, high-risk AR patients were left with limited options. Our Trilogy valve changes that reality."
The company intends to commence launch activity immediately with participating clinical study sites, followed by expansion to additional hospitals across the United States. The Trilogy system previously received CE Mark approval in Europe in 2021 and has been used in more than 1,200 commercial procedures in Europe.
Regulatory and Competitive Landscape
The approval comes amid significant regulatory scrutiny of the TAVR market. Edwards Lifesciences (搜索) had attempted to acquire JenaValve for $1.2 billion in July 2024, alongside heart failure specialist Endotronix. However, the U.S. Federal Trade Commission (搜索) sued Edwards to halt the planned acquisition in August 2025, claiming it would eliminate competition in the TAVR-AR space.
The U.S. District Court for the District of Columbia agreed with the FTC, approving an injunction motion in January 2026 that ended Edwards' planned acquisition of JenaValve. Edwards had previously acquired JC Medical (搜索), another company developing TAVR-AR devices, in August 2024.
According to GlobalData market analysis, the global TAVR market is growing at a compound annual growth rate of over 7% and is projected to reach $13.8 billion in 2035, up from almost $7 billion in 2025. Analysts have suggested that AR's addition as a new TAVR indication could potentially push the market's growth rate into double digits.